Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy.

Raykov, Zahary

Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. [electronic resource] - International journal of cancer Jun 2014 - 2572-82 p. digital

Publication Type: Journal Article

1097-0215

10.1002/ijc.28597 doi


Animals
Antimetabolites, Antineoplastic--therapeutic use
Apoptosis--drug effects
Blotting, Western
Cell Proliferation--drug effects
Deoxycytidine--analogs & derivatives
Drug Synergism
Fluorescent Antibody Technique
Humans
Hypoxia--drug therapy
Hypoxia-Inducible Factor 1, alpha Subunit--antagonists & inhibitors
Inositol Phosphates--therapeutic use
Liver Neoplasms--drug therapy
Male
Mice
Mice, Inbred NOD
Mice, SCID
Neovascularization, Pathologic
Oxygen--metabolism
Pancreatic Neoplasms--drug therapy
RNA, Messenger--genetics
Rats
Rats, Inbred Lew
Real-Time Polymerase Chain Reaction
Reverse Transcriptase Polymerase Chain Reaction
Tumor Cells, Cultured
Gemcitabine